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The mucosal immune system has bidirectional tasks to mount an eﬀective defense against invading harmful pathogens and to
suppress the immune response to alimentary antigens and commensal bacterial ﬂora. Oral tolerance is a suppression of the
mucosal immune pathway related to a speciﬁc immunophenotype of the dendritic cells and an induction of the regulatory T
cells as well as with the silencing of the eﬀector T cell response by anergy and deletion. The physiological dynamic process of
the anatomical and functional maturation of the immune system occurring in children during pre- and postnatal periods is a
signiﬁcant factor, having an impact on the ﬁne balance between the activation and the suppression of the immune response. In
this paper, mechanisms of mucosal immunity and tolerance induction in terms of maturational issues are discussed with a special
emphasis on the implications for a novel therapeutic intervention in allergic diseases via the sublingual route.
1.Introduction
The mucosal immune system comprises the lymphoid-
associated structures of the nasal, bronchial, gastrointestinal,
and genitourinary tracts as well as lacrimal, salivary, and
lactating mammary glands and the synovium of joints. It is
composed of a dynamic network of highly specialized com-
ponentsoftheinnateandadaptiveimmuneresponses,which
give rise to the functional common mucosal immune system
(CMIS) and ensure ﬁne, organ-speciﬁc balance between
activation and suppression. The fundamental challenge of
m u c o s a li m m u n er e s p o n s ei st op r e v e n te ﬀectively the entry
of invading pathogens and the development and the dissem-
inating of infection, whereas simultaneously its exposition to
the external environment and to a high antigenic load elicits
immune tolerance. These interrelated processes of active
promotion and suppression of immunity provide a defense
against microorganisms and neoplasms and protect against
inﬂammatory pathologies such as allergy and autoimmunity
as well. To maintain the immune homeostasis in the oral
mucosa which represents the entry port to the gastrointesti-
nal tract, protolerogenic mechanisms take place in this tissue
and dominate over active immune responses.
The development of mucosal immunity in children is a
time-dependent process initiated in the intrauterine growth
and is continuous during the postnatal period. Despite
the anatomical and functional immaturity of the mucosal
immune system and crosstalk between innate and adaptive
immuneresponses,infantsandyoungchildrenarecapableof
mounting eﬀective immune defense mechanisms. However,
during this age, an imperfect regulatory immune response,
which is of crucial importance in developing oral mucosal
immunity, may pose an increased risk of food allergies. If
developing new strategies of immunotherapy which exploit
the establishing of an oral mucosal tolerance has a rationale
in pediatric patients is here the subject of discussion.
2. Mucosal Defense Mechanisms
2.1. Mucosal Barrier. Extensive noncellular physical bar-
riers and chemical processes as well as cellular components2 Journal of Allergy
constitute mucosal barriers to antigen entry in the mucosa-
associated lymphoid tissue (MALT). Structural diﬀerentia-
tion of the mucosal epithelium and the appearance of inter-
cellular tight junctions lead to the formation of an anatom-
ical basis for an epithelial barrier. A signiﬁcant protective
barrier is constituted by the presence of digestive enzymes
starting in the mouth and extending down to the stomach,
the small bowel, and the colon, which not only allow the
process of digestion, but also modify potentially immuno-
genic antigens and alter antigen exposure. Mucin glycopro-
teins, lining the surface epithelium, produce a barrier in
which particles and pathogens are trapped and protect the
underlying epithelium (the so-called nonimmune exclusion)
as well as serving as a reservoir for the secretory IgA [1].
A number of antimicrobial components of saliva contribute
to protection against microbial colonization and infection.
Theseincludepeptidessuchassalivaryperoxidase,lysozyme,
lactoferrin, cystatins, SLPI (secretory leukocyte protease
inhibitor), agglutinin, peptides of the histatin family, and
cathelicidin (LL-37) as well as α-a n dβ-defensins, which
are expressed and secreted by salivary glands and/or ducts.
In addition to exerting an antimicrobial response, these
peptides facilitate and amplify innate and adaptive immune
responses [2, 3]. Interestingly, it has been recently demon-
strated that the expression and antimicrobial activity of
cathelicidin in the oral mucosa is induced by vitamin D
[4, 5].
2.2. Innate Mucosal Immune Response. The crucial elements
of the innate arm of immunity are pattern recognition
receptors(PRRr),suchasToll-likereceptors(TLRr),retinoid
acid-inducible gene-I- (RIG-I-) like receptors (RLRr) and
nucleotide-binding oligomerization domain (NOD)-like re-
ceptors (NLRr), which recognize pathogen-associated mo-
lecular patterns (PAMPs) and molecular structures speciﬁc
for microbial pathogens. Signaling by pattern-recognition
receptors on antigen-presenting cells induces costimulatory
molecules and cytokines, and furthermore activating a re-
sponse in B and T cells. Thestimulation of Toll-like receptors
by PAMPs initiates signaling cascades that involve a num-
ber of proteins, including MyD88 (myeloid diﬀerentiation
primary response gene 88), IRAK (interleukin- (IL-) recep-
tor associated kinase), Toll/IL-1 receptor (TIR) domain-
containing adapter-inducing interferon (IFN)-β (TRIF).
Subsequent activation of nuclear factor NFκB triggers the
production of proinﬂammatory cytokines, such as tumor
necrosis factor (TNF)-α, IL-1, and IL-12, which direct adap-
tive immune responses. Functional cooperation and cross-
regulation between TLRs and the complement components,
such as C1q, properdin, and the mannose-binding lectin,
using the pattern recognition strategy has been demon-
strated. The complement-TLR interplay reinforces innate
immunity or regulates excessive inﬂammation, through
synergistic or antagonistic interactions [6]. Moreover, ﬁcolin
molecules(L-,M-,andH-ﬁcolin)whichrecognizepathogen-
associated molecular patterns and initiate the lectin pathway
of complement activation are thus a further component
of mucosal immunity linking innate and adaptive immune
responses [7].
The migration of T and B cells from the lymph nodes to
the mucosa, which is related to the activation, recirculation,
and homing of lymphocytes is controlled by the speciﬁc sys-
temofintegrin-typemolecules,selectins[8]andchemokines
[9].
2.3. Adaptive Immune Response. The mucosal immune sys-
tem has generated two arms of an adaptive response, namely,
antigen exclusion, performed by diﬀerent T cell subsets, B
cells and secretory antibodies to inhibit or modulate adher-
ence or colonization of microorganisms and prevent pene-
tration of potentially harmful antigens, as well as suppres-
sive mechanisms to avoid overreaction against innocuous
substances which are in contact with the mucosal surfaces. A
central role in this interrelated network of lymph cell subsets
is played by dendritic cells (DCs), which are important
initiators of adaptive immunity. DC prime na¨ ıve T cells
to expand clonally and diﬀerentiate into T-cell subsets—T
helper Th1, Th2, Th17, or T regulatory (Treg) cells. It has
been demonstrated that these cells may have discrete subsets
and functions, namely, CXC3CR1(+)DC which promote
Th1/Th17 cell diﬀerentiation, whereas CD103(+)DC induce
Treg cell diﬀerentiation on an animal model [10]. At the
mucosal site, dendritic cells and T lymph cells interact with
B cells promoting their diﬀerentiation and the production
of antibodies. Most immunoglobulin class-switching is T
cell dependent; however, it has been demonstrated that T-
cell independent process may also occur, whereby DC and
mucosal epithelial cells excrete BAFF (B cell activating factor
belonging to the TNF family) or APRIL (a proliferation
inducing ligand) directly stimulating B cells to become IgA
secreting plasma cells [11, 12]. IgA is the major class of
antibodies in mucosal secretions and occurs predominantly
in a secretory IgA (sIgA) form along with secretory IgM
(sIgM). The distribution of IgA subclasses varies at diﬀerent
mucosal sites—in the salivary glands and oral mucosa IgA1,
associated with a response to protein antigens predominates,
whereas in the distal portion of the gastrointestinal tract
mainly IgA2, active in response to polysaccharide antigens
is found [13]. The recently characterized Th17 lymphocytes
subset is important for the induction of a mucosal adaptive
immune response. It has been demonstrated that IL-17
elevates secretory IgA levels by upregulating A polymeric
immunoglobulin receptor expression in mucosal epithelia
[14]a n dp r o m o t e sBc e l ld i ﬀerentiation in IgA-secreting
plasma cells on a T cell-independent manner [15]. Further-
more, IL-17 plays a protective role in infectious diseases at
the oral mucosa through the recruitment of neutrophils and
extracellular pathogen clearance [16].
3. MaturationofMucosalImmunityinChildren
3.1. Ontogeny of Mucosal Immunity During Prenatal Period.
Thestructuresofthemucosalimmunesystemarefullydevel-
oped by the 28 gestational week, and thus, premature infants
older than 28 weeks of gestation are capable of mounting an
eﬀective mucosal immune response [13]. Mucosal epithelial
barrier formation commences from gestational week 10;Journal of Allergy 3
however, the immaturity of intercellular tight junctions
results in paracellular permeability, which is advantageous in
the intrauterine period by allowing a bidirectional exchange
of bioactive molecules between amniotic ﬂuid and fetal
serum [17]. Salivary amylase, lysozyme, and lactoferrin
concentrations are most prominent in the fetal period as
demonstrated by Thrane et al. [18], aﬀording nonspeciﬁc
protection in the absence of eﬀective speciﬁc secretory
immunity. Indeed, in the absence of intrauterine infection,
the mucosal immune system is essentially devoid of IgA-
containing lymphocytes, and until birth, there are no active
B cells in the intestinal lymphoid follicles or bronchus-
associated lymphoid tissue (BALT). In the salivary glands,
IgM positive cells have been reported from 110–140 days
of gestation and IgA positive cells with predominance of
IgA1 subclass at 180 days of gestation, but no IgD-, IgG-
, and IgE-producing cells have been identiﬁed by the same
authors[18].Theappearanceofsecretoryantibodiesinutero
can be explained by the possibility that a fetus could have
been exposed to bacterial or viral protein antigens or by
the induction of a fetal immune response by maternal anti-
idiotypic antibodies.
3.2. Postnatal Maturation of Mucosal Immunity. Mucosal
permeability is rapidly reduced within the ﬁrst 48 hours
after birth. In the oral mucosa, disappearance of maternally
derivedIgGreﬂectsthispostnatalmucousmembraneclosure
[19]. This maturational process of the gut barrier function
is enhanced by human milk [20]a sw e l la sb ye a r l yi n t e s t i -
nal colonization with lactobacilli and biﬁdobacteria [21].
The rapid increase of innate defense factors, such as salivary
lysozyme, lactoferrin, and amylase during the ﬁrst six post-
natal months reported by Thrane et al. [18] may provide the
infant necessary protection during the period when speciﬁc
adaptive immunity at mucosal sites is not fully developed.
Postnatal maturation of B lymph cell at mucosal surfaces
has its peak from birth until the 12 week of age and
corresponds with the increase of IgG-producing cells in the
parotid salivary glands. Secretory IgM antibodies appear
in mucosal secretions only transiently during early infancy.
IgA-producing immunocytes, albeit they increase in number
during neonatal period and reach an initial peak about 4–
6 postnatal weeks, approach the low normal adult level at
about 18 months of age, subsequently with small increase
throughout early childhood [17]. Qualitative changes in
secretory IgA are also seen after birth when a switch from
monomeric to polymeric sIgA is observed, indicating mat-
uration of the mucosal secretory immune system. Further-
more, in the perinatal period, IgA1subclass, associated with
responses to protein antigens, predominates in mucosal
secretions, but IgA2 subclass increases rapidly after birth by
6 months of age to approach adult proportions. This pattern
may also reﬂect postnatal changes in the type and load of
antigenic exposure, in particular to polysaccharide antigens
[22]. Interestingly, in preterm infants sIgA appears in secre-
tions at a similar chronological age as in full-term infants
although its concentrations may be signiﬁcantly lower
until the eighth month of life, as reported by Kuitonen and
Savilahti [23]. However, in contrast to these data, Seidel et al.
[24] demonstrated comparable salivary IgA levels in preterm
and full-term infants, suggesting that the development of the
oral mucosal immunocompetence in preterm infants is well
established within the ﬁrst 9 months of life. In preschool
children, the developmental proﬁle of mucosal immunity
depends on the degree of antigenic challenge they experience
as well as on the exposure to hazardous environmental
agents, such as tobacco smoke [25].
4. The Phenomenon of Mucosal Tolerance
4.1. Induction of Tolerance. In parallel to local defense
mechanisms which protect against invading pathogens, the
mucosal immune system has developed specialized regula-
tory and anti-inﬂammatory mechanisms for eliminating or
tolerating harmless food and airborne antigens as well as
commensalmicroorganisms.Mucosaltoleranceinductionis,
therefore,anactiveprocessandisseenaspreferentialtheTh2
skewed immune response and the downregulation of Th1
cell-mediated delayed type hypersensitivity and antibody
production. These complex regulatory mechanisms include
clonal deletion of T cells, clonal anergy, antigen-driven im-
munosuppression as well as active inhibition by coinhibitory
receptors [26]. Many diﬀerent CD4+ T regulatory (Treg)
cell subsets have been identiﬁed capable of inhibiting the
responses of eﬀector T cells. Thymus-derived CD4+CD25+
Foxp3 (forkhead box protein 3)+Treg cells play a funda-
mental role in maintaining self-tolerance and preventing
autoimmunization as well as contributing to tolerance of
nonself antigens by the inhibition of immune responses
directedatcommensalbacteriaintheintestine[27].Mucosal
Foxp3+ cells have been identiﬁed in the small and large
intestinal mucosa as early as 23 weeks of gestational age,
indicating a potential for intestinal immune regulation im-
mediately after birth [28]. In contrast to thymus-derived
Treg cells, adaptive Treg cells, which are peripherally
induced after feeding protein, are essential for mucosal
tolerance. These include TGF-β- (transforming growth fac-
tor β-) producing Th3 cells, type 1 T regulatory cells (Tr1)
which produce IL-10 as well as Foxp3+Treg cells. The ac-
tive suppressive mechanisms may also induce a “bystander
eﬀect” in that suppressive cytokines released by regulatory
T cells in an antigen-speciﬁc pattern may also suppress
ongoing immune response to an unrelated but anatomically
colocalized antigen [29].
It is worth of note that the term “mucosal tolerance”
is widely used to describe tolerance induction occurring in
the intestinal MALT (mucosa-associated lymphoid tissue),
represented by B cell follicles and M cell containing lym-
phoid epithelium, where the uptaken antigens are passed
to APC (antigen-presenting cells), such as dendritic cells,
macrophages, and B cells. However, in contrast to the
intestine, the oral mucosa lacks inductive site represented by
MALT and most likely local organized lymphoid tissue and
regional lymph nodes play a role in the induction of oral
mucosal tolerance [26].
Dendritic cells, the most important components orches-
trating the mucosal tolerance in the gastrointestinal tract,4 Journal of Allergy
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Figure 1: Exo- and endogenous biological factors determining mucosal immune response proﬁle in childhood.
have an intrinsic noninﬂammatory activation state and a
rich repertoire of receptors expressed by these cells, such
as high-aﬃnity receptor for IgE (FcεRI), high- and low-
aﬃnity receptors for IgG (FcγRI and FcγRII, resp.), Toll-like
receptors (TLR)2, and TLR4 and LPS (lipopolysaccharide)
receptor CD14, are of crucial importance in the induction
of antigen-speciﬁc regulatory T cells. Furthermore, several
factors, such as the nature and dose of antigen, the frequency
of its administration, age at ﬁrst antigen exposure, mater-
nal dietary exposure during pregnancy and breastfeeding,
antigen transmission via breast milk, as well as genetic
background and immunological status of the child inﬂuence
the ﬁne balance between tolerance and eﬀector response
[29]. Exo- and endogenous biological factors determining
mucosal immune response proﬁle in childhood are summa-
rized in Figure 1.
4.2. Role of Breastfeeding. The newborn and infant gut is
hypersensitive to proinﬂammatory stimuli and vulnerable to
pathogens. Breastfeeding not only favors the transmission
of immunocompetence from the mother to the infant, as
reviewedbyChiricoetal.[30],butalsohasimmunomodula-
tory and anti-inﬂammatory properties. The dietary antigens
present in breast milk coupled with immunosuppressive
cytokines, such as IL-10 and TGFβ, promote tolerance to
food antigens and gut microﬂora. It has been demonstrated
in the study by Field et al. [31] that long chain polyunsat-
urated fatty acids in human milk alter the infant’s ability to
produce cytokines enhance the anti-inﬂammatory eﬀect of
IL-10. Soluble TNF-α (tumor necrosis factor) receptors and
IL-1RA (interleukin 1 receptor antagonist) in human milk
eﬀectively inhibit inﬂammatory response elicited by TNF-α
and IL-1, respectively [32], and IL-10 exhibits a suppressive
eﬀect on IL-8 and neutrophilic inﬂammation [33]. Human
milk also contains hormones, such as epidermal growth
factor (EGF), insulin-like growth factor (IGF), as well as
adiponectin, which modulate the immune system by the
regulation of cytokine expression [20].
5. Mucosal Tolerance: An Implication for
Sublingual Immunotherapy
5.1. Oral Mucosal Microenvironment. In the oral mucosa
the network of resident dendritic cells (DCs) is mainly
composed of the myeloid DC from the Langerhans cell
(LC) subtype, expressing CD1a and CD207 antigens (HTA1
and langerin, the LC speciﬁc lectin, corresponding with the
mannose-containing oligosaccharide receptor, respectively),
costimulatory molecules, such as B7.1 (CD80) and B7.2
(CD86) as well as other myeloid markers, eg CD11b (a com-
plementcomponentsreceptor).Thesecellsarealsoequipped
with a very speciﬁc receptor repertoire, such as a high-
aﬃn i t yr e c e p t o rf o rI g E( F c εRI) resulting in allergen uptake
and IgE binding to speciﬁc receptors on their surfaces.
Interestingly, cross-linking of FcεRI on dendritic cells results
in the induction of both pro- and, most importantly, anti-
inﬂammatorymediators,suchasIL-10[34]andindoleamine
2,3-dioxygenase (IDO) [35], which is involved in the sup-
pression of T cell responses and tolerance. The expression
of high- and low-aﬃnity receptors for IgG containing an
immunoreceptor tyrosine inhibitory motif (ITIM) enhances
the induction of antigen-speciﬁc regulatory T cells, as shown
b yS a m s o me ta l .o na na n i m a lm o d e l[ 36]. Furthermore,
TLR4 ligation on the oral DC surface leads to a subsequent
induction of Foxp3 expressing as well as IL10 and TGFβ
producing regulatory T cells [37], which are key players in
oral mucosal tolerance. These unique properties of DC to
drive Treg cells diﬀerentiation relate to their being con-
ditioned by commensal bacteria, TGFβ and IL-10, their
expression of αEβ7 integrin (CD103) and retinoid acid [38].
5.2.ImmunologicalMechanismsofSublingualImmunotherapy
(SLIT). Multidirectional tolerogenic properties of an oralJournal of Allergy 5
immune response warrant antigen-speciﬁc tolerance induc-
tion. Dendritic cells in the oral mucosa, which exhibit the
high aﬃnity receptor for IgE Fc fragment, take up allergens
administered in SLIT and induce speciﬁc immune responses.
An increase of serum IgG4 and IgA, noninﬂammatory and
noncomplement binding isotypes as well as reduced allergen
speciﬁc IgE locally in the target organ have been noted in
the occurrence of increased TGF-β and IL-10 in allergen
speciﬁc peripheral blood mononuclear cells [39]. Similarly,
in the clinical study comprising a group of asthmatic/
rhinitis pediatric patients, reported by Eifan et al. [40] the
immunological mechanisms of SLIT were associated with
signiﬁcant increases of TGF-β and IL-10. Furthermore, T
regulatory cell function has also been demonstrated by
O’Hehir et al. [41], leading to the suppression of the allergen
speciﬁc eﬀector T (CD4+CD25-CD127hi) cell proliferation
and cytokine production. In a recent study of Angelini et
al. [42] the downregulation of the costimulatory molecule
CD86onblooddendriticcells,increasedIL-10anddecreased
I L - 1 2p r o d u c t i o nh a v eb e e nd e m o n s t r a t e di nag r o u po ft e n
childrenwithallergicasthmaandhousedustmitessensitivity
after 12 month of SLIT. These signiﬁcant functional alter-
ations of dendritic cells may contribute to decreased T cell
activation and a shift toward regulatory activity.
5.3. Eﬃcacy and Safety of SLIT in Children. In the light of
the aforementioned considerations regarding developmental
issues of mucosal tolerance in children as well as multiple
endo- and exogenous factors which may have an important
impactonitsoutcome,importantquestionsarisewithregard
to the eﬃciency and safety of SLIT. In meta-analysis studies
performed by several investigators [43–45], comprising of
pediatric patients with allergic asthma treated with SLIT, a
signiﬁcant reduction in the symptom scores and the use of
rescue medication as well as an improvement in lung func-
tion have been demonstrated. It has been well established
that SLIT requires a high allergen dose for its eﬃciency
to facilitate a take-up of suﬃcient amounts of allergens
by sentinel dendritic cells within the oral mucosa or due
to a lack of adjuvants by sublingual administration [46].
Even though a high dose and long courses of medication are
necessary, SLIT is a safe therapeutic option for children, as
has been recently reported by Ferr´ es et al. [47]; although,
in this study, the mild and local adverse reaction rate was
at 23%; however, none of the cases from the study group
showed an anaphylactic reaction. Similarly, in the clinical
s t u d yb yE i f a ne ta l .[ 40] it was demonstrated that SLIT was
associated with clinical improvement and proved to be a safe
mode of immunotherapy. Therefore, as has been stated by
Wahn [48], it seems likely that the induction of tolerance via
the sublingual route to prevent the outset of allergic asthma,
even in younger children, will soon be addressed in clinical
studies.
6. Concluding Remarks
Mucosal immunity is characterized by a speciﬁc matura-
tional pattern initiated in the intrauterine fetal development
and continued during the neonatal period, and in infancy
and childhood, dynamically leading to a highly specialized
immune response. At mucosal sites, a subtle balance occurs
between eﬀective defense mechanisms against the invasion
of harmful pathogens and triggers the limitation of eﬀector
immune reactions to food antigens and commensal ﬂora.
Important factors, such as genetic predisposition and the age
of the host, pre- and postnatal exposure to antigens, as well
as the properties and the dose of antigen contribute to the
development of mucosal tolerance, this being the rationale
of critical importance for sublingual immunotherapy. The
results of hitherto prevailing clinical studies suggest the eﬃ-
cacy and safety of this treatment option in children, hereby
opening new perspectives in pediatric allergology.
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